Performance And Economic Analysis Of Finished Lambs In Feedlot

This study aimed to evaluate animal performance and economic performance of feedlot crossbred lambs (Santa Inês+ - Suffolk) fed different diets based on hay from Cynodon dactylon genotypes, through the use of financial measures considering only the period of feedlot, without relating it to the complete management cycle. A total of 30 intact crossbred Suffolk lambs, identified with earrings, with an average age of 90 days and an average body weight of 21.5 kg were used in this study. Diets were formulated using as treatments a standard concentrate and hay of the Cynodon dactylon genotypes Jiggs, Vaquero, Tifton 68, Coast-Cross, Tifton 85 and Russell in a 60:40 forage-to-concentrate ratio. The treatments were distributed in a randomized complete block design with five replicates. There were significant differences between diets in terms of total expenditure on food, and the highest values were obtained for the Jiggs genotype (BRL 48.96/animal). The animals fed diets based on Tifton 68 hay had a higher rate of return (2.16%) and profitability (34.63%) compared to the other diets. The use of diets based on Tifton 68 hay for feedlot lambs in the finishing phase brings higher economic returns compared to the remaining diets.37129330

Effect of sitagliptin on energy metabolism and brown adipose tissue in overweight individuals with prediabetes:a randomised placebo-controlled trial

Aims/hypothesis: The aim of this study was to evaluate the effect of sitagliptin on glucose tolerance, plasma lipids, energy expenditure and metabolism of brown adipose tissue (BAT), white adipose tissue (WAT) and skeletal muscle in overweight individuals with prediabetes (impaired glucose tolerance and/or impaired fasting glucose). Methods: We performed a randomised, double-blinded, placebo-controlled trial in 30 overweight, Europid men (age 45.9 \xc2\xb1 6.2\xc2\xa0years; BMI 28.8 \xc2\xb1 2.3\xc2\xa0kg/m2) with prediabetes in the Leiden University Medical Center and the Alrijne Hospital between March 2015 and September 2016. Participants were initially randomly allocated to receive sitagliptin (100\xc2\xa0mg/day) (n = 15) or placebo (n = 15) for 12\xc2\xa0weeks, using a randomisation list that was set up by an unblinded pharmacist. All people involved in the study as well as participants were blinded to group assignment. Two participants withdrew from the study prior to completion (both in the sitagliptin group) and were subsequently replaced with two new participants that were allocated to the same treatment. Before and after treatment, fasting venous blood samples and skeletal muscle biopsies were obtained, OGTT was performed and body composition, resting energy expenditure and [18F] fluorodeoxyglucose ([18F]FDG) uptake by metabolic tissues were assessed. The primary study endpoint was the effect of sitagliptin on BAT volume and activity. Results: One participant from the sitagliptin group was excluded from analysis, due to a distribution error, leaving 29 participants for further analysis. Sitagliptin, but not placebo, lowered glucose excursion (\xe2\x88\x9240%; p < 0.003) during OGTT, accompanied by an improved insulinogenic index (+38%; p < 0.003) and oral disposition index (+44%; p < 0.003). In addition, sitagliptin lowered serum concentrations of triacylglycerol (\xe2\x88\x9229%) and very large (\xe2\x88\x9246%), large (\xe2\x88\x9235%) and medium-sized (\xe2\x88\x9224%) VLDL particles (all p < 0.05). Body weight, body composition and energy expenditure did not change. In skeletal muscle, sitagliptin increased mRNA expression of PGC1\xce\xb2 (also known as PPARGC1B) (+117%; p < 0.05), a main controller of mitochondrial oxidative energy metabolism. Although the primary endpoint of change in BAT volume and activity was not met, sitagliptin increased [18F] FDG uptake in subcutaneous WAT (sWAT; +53%; p < 0.05). Reported side effects were mild and transient and not necessarily related to the treatment. Conclusions/interpretation: Twelve weeks of sitagliptin in overweight, Europid men with prediabetes improves glucose tolerance and lipid metabolism, as related to increased [18F] FDG uptake by sWAT, rather than BAT, and upregulation of the mitochondrial gene PGC1\xce\xb2 in skeletal muscle. Studies on the effect of sitagliptin on preventing or delaying the progression of prediabetes into type 2 diabetes are warranted. Trial registration: ClinicalTrials.gov NCT02294084. Funding: This study was funded by Merck Sharp & Dohme Corp, Dutch Heart Foundation, Dutch Diabetes Research Foundation, Ministry of Economic Affairs and the University of Granada

Systematic Review of Medicine-Related Problems in Adult Patients with Atrial Fibrillation on Direct Oral Anticoagulants

New oral anticoagulant agents continue to emerge on the market and their safety requires assessment to provide evidence of their suitability for clinical use. There-fore, we searched standard databases to summarize the English language literature on medicine-related problems (MRPs) of direct oral anticoagulants DOACs (dabigtran, rivaroxban, apixban, and edoxban) in the treatment of adults with atri-al fibrillation. Electronic databases including Medline, Embase, International Pharmaceutical Abstract (IPA), Scopus, CINAHL, the Web of Science and Cochrane were searched from 2008 through 2016 for original articles. Studies pub-lished in English reporting MRPs of DOACs in adult patients with AF were in-cluded. Seventeen studies were identified using standardized protocols, and two reviewers serially abstracted data from each article. Most articles were inconclusive on major safety end points including major bleeding. Data on major safety end points were combined with efficacy. Most studies inconsistently reported adverse drug reactions and not adverse events or medication error, and no definitions were consistent across studies. Some harmful drug effects were not assessed in studies and may have been overlooked. Little evidence is provided on MRPs of DOACs in patients with AF and, therefore, further studies are needed to establish the safety of DOACs in real-life clinical practice

Pervasive gaps in Amazonian ecological research

Biodiversity loss is one of the main challenges of our time, and attempts to address it require a clear understanding of how ecological communities respond to environmental change across time and space. While the increasing availability of global databases on ecological communities has advanced our knowledge of biodiversity sensitivity to environmental changes, vast areas of the tropics remain understudied. In the American tropics, Amazonia stands out as the world's most diverse rainforest and the primary source of Neotropical biodiversity, but it remains among the least known forests in America and is often underrepresented in biodiversity databases. To worsen this situation, human-induced modifications may eliminate pieces of the Amazon's biodiversity puzzle before we can use them to understand how ecological communities are responding. To increase generalization and applicability of biodiversity knowledge, it is thus crucial to reduce biases in ecological research, particularly in regions projected to face the most pronounced environmental changes. We integrate ecological community metadata of 7,694 sampling sites for multiple organism groups in a machine learning model framework to map the research probability across the Brazilian Amazonia, while identifying the region's vulnerability to environmental change. 15%–18% of the most neglected areas in ecological research are expected to experience severe climate or land use changes by 2050. This means that unless we take immediate action, we will not be able to establish their current status, much less monitor how it is changing and what is being lost

Extratos de plantas de cobertura no desenvolvimento de Sclerotinia sclerotiorum

Extratos vegetais podem interferir no ciclo de vida dos fitopatógenos por promover ou inibir o desenvolvimento. Com base nessa propriedade, este trabalho foi realizado com o objetivo de estudar o efeito dos extratos aquosos das plantas de cobertura crotalária (Crotalaria juncea), braquiária (Brachiaria ruziziensis), capim-mombaça (Panicum maximum cv. mombaça), milheto (Pennisetum glaucum), feijão-guandu-anão (Cajanus cajan) e estilosantes (Stylosanthes capitata x Stylosanthes macrocephala) sobre o crescimento micelial, germinação carpogênica e micelial dos escleródios e germinação dos ascósporos do fungo Sclerotinia sclerotiorum. As etapas do experimento foram desenvolvidas em casa de vegetação, câmaras de crescimento e laboratório. As concentrações dos extratos utilizadas foram de 1%, 5%, 10% e 25%. Para verificar a influência dos extratos sobre a germinação micelial e carpogênica dos escleródios, foi utilizada somente a concentração de 25%. Os resultados sobre o crescimento micelial mostraram que o extrato da planta de Stylosanthes sp. inibiu o desenvolvimento do patógeno apenas na concentração de 25%. Para a germinação micelial dos escleródios, verificou-se que os extratos induziram a germinação 12 horas após a instalação do experimento, exceto o Stylosanthes sp. Na germinação dos ascósporos, apenas o extrato de Stylosanthes sp. impediu a germinação